Presentation AHA 2016 Arterial Revascularization Trial (ART) Presenter: David P. Taggart November 15, 2016 REGISTER for free or LOG IN to view this content Coronary ACS/AMI Cardiac Surgery Presentation AHA 2016 Up Next Presentation AHA 2016 PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy Presenter: Michael Gibson November 15, 2016 More slides + Presentation AHA 2016 Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial Presenter: David M Kaye November 15, 2016 Presentation AHA 2016 The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I) Presenter: Michael Gibson November 15, 2016 We Recommend
Presentation AHA 2016 PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy Presenter: Michael Gibson November 15, 2016
Presentation AHA 2016 Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial Presenter: David M Kaye November 15, 2016
Presentation AHA 2016 The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I) Presenter: Michael Gibson November 15, 2016